生物来源
mouse
质量水平
100
500
偶联物
unconjugated
抗体形式
diluted ascites fluid
抗体产品类型
primary antibodies
克隆
121SLE, monoclonal
描述
For In Vitro Diagnostic Use in Select Regions (See Chart)
形式
buffered aqueous solution
种属反应性
human
包装
vial of 0.1 mL concentrate (399M-14)
vial of 0.5 mL concentrate (399M-15)
bottle of 1.0 mL predilute (399M-17)
vial of 1.0 mL concentrate (399M-16)
bottle of 7.0 mL predilute (399M-18)
制造商/商品名称
Cell Marque™
技术
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
同位素/亚型
IgM
控制
colon, colon carcinoma
运输
wet ice
储存温度
2-8°C
可视化
cytoplasmic
一般描述
Carbohydrate Antigen 19-9 (CA19-9) is a sialylated Lewis A blood group antigen. It issynthesized by glycosyltransferases and has been identified as a component of gangliosides,glycoproteins, and mucins. Anti-CA19-9 reacts with epithelial cells of the normal pancreas,stomach, and colon as well as various adenocarcinomas, including pancreatic, gastric, andcolorectal adenocarcinomas.
质量
 IVD |  IVD |  IVD |  RUO |
联系
CA19-9 Positive Control Slides, Product No. 399S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
外形
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
制备说明
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
其他说明
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法律信息
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our 产品选型工具.
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Basso D, et al.
Medical Science Research, 17, 13-14 (1989)
Seric CA 19.9 levels in patients with non tumoral pathologies. Our experience in 892 cases.
G Encabo et al.
Bulletin du cancer, 73(3), 256-259 (1986-01-01)
Y Tabuchi et al.
Cancer, 66(7), 1529-1533 (1990-10-01)
The correlation between CA19-9 levels of portal and peripheral venous blood, and immunohistochemical variables of cancer lesions was examined in 53 gastric cancer patients and eight patients with benign diseases. Immunohistochemically, CA19-9 was found in 33 (62.5%) of 53 primary
Gatalica Z, et al.
Appl. Immunohistochem., 2(3), 205-211 (1994)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门